Vermont Medicaid spending on GLP-1 drugs

How much did Vermont Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $18.5 million for GLP-1 drugs paid through Vermont Medicaid in 2025, across at least 17,163 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 38 rows of 133, so these figures are floors.

Pharmacies were reimbursed at least $5.8 million for GLP-1 drugs paid through Vermont Medicaid in 2026 (quarter 1 only, as posted so far), across at least 5,237 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 6 rows of 33, so these figures are floors.

By year and ingredient

2020at least $640,190No data$2,441,012at least $1,103,647at least $459,221No dataat least $22,751at least $4,666,821
2021at least $1,074,778No data$2,554,395at least $4,580,591at least $179,837No dataSuppressedat least $8,389,601
2022at least $1,870,171Suppressed$2,252,499at least $8,633,226at least $81,586No dataSuppressedat least $12,837,483
2023at least $6,018,853at least $103,362$1,698,277$9,062,470at least $38,176No dataSuppressedat least $16,921,137
2024at least $9,894,383at least $1,162,618at least $595,917$4,592,989at least $10,444SuppressedSuppressedat least $16,256,350
2025at least $9,444,647at least $2,800,488at least $165,363at least $6,126,818SuppressedNo dataSuppressedat least $18,537,316
2026 (Q1)at least $2,183,174$1,555,324at least $34,358$2,035,056No dataNo dataSuppressedat least $5,807,912

By product, 2025

Ozempic$8,766,8097,8130 of 12
Rybelsus$542,8934390 of 12
Wegovyat least $134,946at least 14111 of 20
Mounjaro$1,724,5451,7240 of 24
Zepboundat least $1,075,942at least 1,0599 of 23
Liraglutide (generic name listing)SuppressedSuppressed12 of 12
Victoza$165,3632250 of 8
Trulicityat least $6,126,818at least 5,7621 of 17
BydureonSuppressedSuppressed2 of 2
XultophySuppressedSuppressed3 of 3

By quarter, 2025

Q1 2025at least $4,056,465at least 3,78512 of 32
Q2 2025at least $4,583,335at least 4,23313 of 35
Q3 2025at least $4,810,876at least 4,46910 of 36
Q4 2025at least $5,086,640at least 4,6763 of 30

By quarter, 2026 (posted so far)

Q1 2026at least $5,807,912at least 5,2376 of 33

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.